JG
AKRO

Jefferies Group’s Akero Therapeutics AKRO Stock Holding History

Jefferies Group’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1.02M Buy
+30,000
New +$459K 0.01% 808

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Jefferies Group's AKRO Position: Q3 2022 in Review

Jefferies Group opened a new position in Akero Therapeutics (AKRO) in Q3 2022: 8,617 shares worth $293K. The stake represents ﹤0.01% of the portfolio and ranks #1239 among its holdings.

146 funds tracked by Wall St. Rank hold AKRO as of Q3 2022.

  • Jefferies Group held 8,617 shares of Akero Therapeutics worth $293K as of Q3 2022.
  • Akero Therapeutics was a new Jefferies Group position in Q3 2022.
  • Akero Therapeutics made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1239 holding.
  • 146 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.